Cannabis Co-Use and Endocannabinoid System Modulation in Tobacco Use Disorder: A Translational Systematic Review and Meta-Analysis

Gabriel P. A. Costa, M.D.[1,2]; Oscar Gómez, M.D.[3]; Mayte A. Cerezo-Matias, B.S.[1]; Melissa C. Funaro, M.S., M.L.S[4]; Mehmet Sofuoglu, M.D., Ph.D. [1,5]; Joao P. De Aquino, M.D. [1,2,5]

1. Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States
2. Clinical Neuroscience Research Unit (CNRU), Connecticut Mental Health Center (CMHC), New Haven, CT, United States
3. Cellular and Molecular Immunology Group - InmuBo, Universidad El Bosque, Bogotá, Colombia
4. Harvey Cushing/John Hay Whitney Medical Library, Yale University, New Haven, CT, USA
5. VA Connecticut Healthcare System, West Haven, CT, USA

Corresponding Authors:
Joao P. De Aquino, M.D.
Department of Psychiatry
Yale School of Medicine
34 Park St, 333B, New Haven, CT 06519
Phone: 203-937-5711 Ext. 2916
Fax: 203-937-3422
Email: joao.deaquino@yale.edu
ORCID: https://orcid.org/0000-0001-7357-8215

Gabriel P. A. Costa, M.D.
Department of Psychiatry
Yale School of Medicine
34 Park St, 332, New Haven, CT 06519
Email: gabriel.costa@yale.edu
ORCID: https://orcid.org/0009-0007-8702-5436

Funding: This work was supported by the grant K23DA052682 from the National Institute on Drug Abuse (NIDA) to Dr. De Aquino. The other authors received no specific funding for this work.

Competing Interests: Dr. De Aquino has received research support from Jazz Pharmaceuticals and Ananda Scientific and has served as a paid consultant for Boehringer Ingelheim. The remaining authors declare no conflict of interest.

Abstract

Tobacco use disorder (TUD) remains a leading cause of preventable mortality, and existing pharmacotherapies yield 12-month abstinence rates below 30%. As cannabis legalization expands, approximately 18-22% of people who use tobacco report concurrent cannabis use, yet the impact of co-use on cessation outcomes and the therapeutic potential of endocannabinoid system (ECS) modulation remain unclear. We conducted a translational systematic review and meta-analysis following PRISMA 2020 guidelines, searching Ovid MEDLINE, Embase, APA PsycInfo, and Web of Science through January 2026 (PROSPERO: CRD420250652724). Three study categories were eligible: observational studies of cannabis co-use and cessation outcomes; preclinical studies of cannabinoid modulators on nicotine-related behaviors; and human experimental studies of ECS-targeted interventions. Of 4,869 records screened, 52 studies met inclusion criteria. Meta-analysis of 18 observational studies (N=229,630) revealed that cannabis use was associated with 35% lower odds of achieving tobacco smoking cessation (OR=0.65; 95% CI: 0.55-0.78; $p<0.0001$; $I^2=88.1\%$). Preclinical evidence (15 studies) demonstrated that CB1 receptor antagonists robustly reduced nicotine self-administration and reinstatement, while cannabidiol (CBD) attenuated both nicotine intake and withdrawal without affecting food reinforcement. Clinical translation of CB1 receptor inverse agonists failed due to psychiatric adverse effects, but CBD showed promise by reducing cigarette consumption by 40%, reversing attentional bias to smoking cues, and alleviating withdrawal severity. These findings distinguish naturalistic cannabis exposure from potentially beneficial targeted ECS modulation, and support CBD as a promising candidate for adequately powered tobacco cessation trials.

1. Introduction

Tobacco use disorder (TUD), characterized by compulsive tobacco use and loss of control over intake, is a leading cause of preventable mortality globally, accounting for more than 7 million deaths annually and imposing substantial burden through cardiovascular disease, malignancy, and respiratory illness[1,2]. In the U.S., approximately 28.3 million adults currently smoke tobacco cigarettes (combustible and electronic), and despite decades of public health efforts, the majority of quit attempts fail, with less than 10% of tobacco smokers achieving long-term abstinence without pharmacological support[3,4].

Currently, there are three FDA-approved first-line pharmacological treatments for TUD: nicotine replacement therapy (NRT), bupropion, and varenicline. They demonstrate clinically meaningful efficacy, doubling cessation rates compared to placebo[3,5]. However, 12-month abstinence rates remain below 30%[3], and treatment response exhibits substantial interindividual heterogeneity that is not fully explained by demographic or clinical characteristics[6,7]. This therapeutic ceiling, combined with the limited range of pharmacological mechanisms targeted by available pharmacotherapies, underscores the need to identify novel therapeutic approaches for TUD.

Against the backdrop of limited treatments for TUD, the rapid expansion of cannabis legalization across North America and Europe has introduced a parallel consideration: the rising prevalence of cannabis-tobacco co-use. National survey data indicate that approximately 18-22% of people who currently use tobacco report concurrent cannabis use[8-10]. Cannabis and tobacco are frequently co-administered within the same product (e.g., blunts, spliffs), a practice that creates pharmacological interactions potentially reinforcing use of both substances[11-13]. Epidemiological evidence suggests that people who co-use tobacco and cannabis exhibit greater nicotine dependence severity, increased frequency of failed quit attempts, and elevated relapse vulnerability compared to people who use tobacco only[11,13-15]. As cannabis access continues to expand, understanding whether and how co-use impacts tobacco smoking

cessation outcomes (henceforth, 'smoking cessation' refers specifically to tobacco smoking cessation) has become an urgent clinical priority.

The potential for cannabis-tobacco interactions—and the therapeutic relevance of cannabinoid pharmacology for nicotine dependence—derives from extensive crosstalk between the endocannabinoid and nicotinic cholinergic systems. The endocannabinoid system (ECS) comprises cannabinoid receptors (primarily CB1 and CB2), endogenous ligands including anandamide (AEA) and 2-arachidonoylglycerol (2-AG), and metabolic enzymes such as fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL)[16]. CB1 receptors (CB1R)—the most abundant G-protein coupled receptors in the central nervous system[17]—are densely expressed throughout reward-related circuitry, including the ventral tegmental area (VTA), nucleus accumbens (NAc), prefrontal cortex, and amygdala, where they serve as retrograde modulators of glutamatergic and GABAergic transmission[18,19]. Critically, these regions overlap substantially with the neural substrates of nicotine reinforcement and withdrawal[20].

Convergent evidence supports bidirectional modulation between these systems. Acute nicotine administration increases endocannabinoid levels in reward-relevant brain regions[21-23], while chronic nicotine exposure induces neuroadaptive changes in CB1R expression and endocannabinoid tone that may contribute to dependence and withdrawal[23-26]. Genetic association studies have identified polymorphisms in cannabinoid receptor genes (CNR1) and FAAH that predict nicotine dependence severity and cessation outcomes[27,28]. This neurobiological intersection raises two distinct but complementary clinical questions. First, if exogenous cannabinoid exposure engages the same circuitry that modulates nicotine reinforcement, does co-use of tobacco and cannabis alter tobacco cessation outcomes? Second, can pharmacological interventions targeting specific ECS components—distinct from uncontrolled cannabis exposure—provide therapeutic benefit for TUD?

The present systematic review and meta-analysis aims to address both questions through an integrated translational framework. We first synthesize observational evidence

examining whether cannabis use predicts smoking cessation outcomes among individuals receiving cessation interventions. We then evaluate preclinical and human experimental studies of ECS modulators—including CB1R antagonists, endocannabinoid enzyme and transport inhibitors, and cannabidiol (CBD)—as potential pharmacotherapies. By integrating epidemiological and pharmacological perspectives, we aim to (1) quantify the clinical impact of cannabis co-use on cessation success, (2) identify ECS mechanisms with therapeutic promise, (3) elucidate translational barriers, and (4) clarify the distinction between potentially harmful naturalistic cannabinoid exposure and potentially beneficial targeted pharmacotherapy.

2. Methods

This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines[29]. The protocol was prospectively registered with PROSPERO CRD420250652724.

2.1 Search Strategy

We searched Ovid MEDLINE, Embase, APA PsycInfo, and Web of Science from inception through December 2024, with a final search update conducted in January 2026. The search strategy combined terms related to the ECS (cannabinoid, endocannabinoid, CB1, CB2, anandamide, 2-AG, CBD, tetrahydrocannabinol, rimonabant, FAAH) with nicotine/tobacco-related terms (nicotine, tobacco, smoking, cigarette, cessation, withdrawal). Reference lists of eligible studies and relevant systematic reviews were manually screened. Complete search strategies are provided in **Supplementary eMethods**.

2.2 Eligibility Criteria

Given the review's dual objectives—(1) evaluating whether naturalistic cannabis co-use is associated with smoking cessation outcomes and (2) assessing whether targeted ECS modulation offers therapeutic potential for TUD—, three study categories were eligible: (1) Observational studies examining the association between cannabis use (exposure) and smoking abstinence or relapse among individuals receiving any cessation intervention. Studies were required to report odds ratios, relative risks, or sufficient data permitting their calculation. (2) Preclinical studies comprising controlled experiments using animal models examining effects of cannabinoid system modulators on nicotine-consumption, including self-administration, reinstatement of nicotine seeking, and conditioned place preference. (3) Human experimental studies including randomized controlled trials, crossover designs, and laboratory paradigms evaluating cannabinoid interventions for tobacco-related outcomes (consumption, craving, withdrawal, cue reactivity, cessation) or examining mechanistic interactions between cannabis and tobacco.

2.3 Data Extraction and Synthesis

Two reviewers (G.C. and O.G.) independently screened titles/abstracts and full texts, with discrepancies resolved by consensus discussion. Data extraction employed standardized forms tailored to each study category. For observational studies, we extracted odds ratios (or calculated them from reported data), confidence intervals, sample sizes, cannabis use definitions, cessation outcomes, and adjustment variables.

Only the observational studies examining cannabis co-use and smoking cessation outcomes were considered meta-analyzable, as they reported a common effect measure (odds ratios for cessation) with sufficient methodological homogeneity for quantitative pooling. Quantitative synthesis of preclinical and human experimental studies was precluded by the heterogeneity in species, compounds, dosing regimens, outcome measures, and study designs.

For the meta-analyzable observational studies, we employed inverse-variance random-effects models with restricted maximum likelihood estimation of between-study variance (τ^2). Heterogeneity was assessed using Cochran's Q statistic, τ^2, and I^2. Subgroup analyses examined potential effect modification by intervention setting. For preclinical and human experimental studies, synthesis was narratively organized by cannabinoid mechanism given heterogeneity in designs and outcomes.

2.4 Risk of Bias Assessment

We assessed risk of bias in randomized trials using the Cochrane Risk of Bias 2 (RoB 2) tool and observational studies using the Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I) tool. No formal quality assessment was conducted for preclinical studies due to lack of widely accepted tools for animal studies.

3. Results

Database searches identified 4,869 records after deduplication. Following title and abstract screening and a full-text review of 216 articles, 52 studies met the inclusion criteria: 18 observational studies examining cannabis as a predictor of cessation, 15 preclinical studies evaluating cannabinoid modulators, and 19 human experimental studies (**Figure 1**). The results are organized to first examine the impact of co-use on cessation (observational evidence), followed by an exploration of the therapeutic potential of cannabinoid interventions (preclinical and human experimental evidence).

Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Flowchart Diagram.



Flow diagram illustrating the study selection process. A total of 9,413 records were identified across four databases. After removing 4,544 duplicates, 4,869 records were screened by title and abstract, and 216 full-text articles were assessed for eligibility. 52 studies met inclusion criteria: 18 observational, 15 preclinical, and 19 clinical.

3.1 Cannabis Co-Use and Smoking Cessation: Observational Evidence

Eighteen observational studies contributing 20 independent estimates (total N=229,630) examined whether cannabis use predicted smoking cessation outcomes among individuals receiving cessation interventions. Follow-up ranged from end-of-treatment to 12 months, with 6-month assessment most common.

Meta-analysis yielded a pooled odds ratio of 0.65 (95% CI: 0.55-0.78; $p<0.0001$), indicating that people who use cannabis had 35% lower odds of achieving cessation compared

to people who do not use cannabis (**Figure 2**). Between-study heterogeneity was high (I^2=88.1%; 95% CI: 83.1-91.7%; τ^2=0.10; Cochran's Q=160.24, df=19, p<0.0001), reflecting substantial variability in effect magnitude. Visual inspection of the funnel plot did not reveal marked asymmetry (**Supplement Figure S1**) and neither Egger's regression test (p = 0.071) nor Begg's rank correlation test (p = 0.948) indicated significant publication bias.

Figure 2. Forest Plot of the Association Between Cannabis Use and Smoking Cessation Outcomes in Observational Studies



Random-effects meta-analysis of 18 observational studies (20 independent estimates; N=229,630) examining the odds of smoking cessation among people who use cannabis compared to people who do not use cannabis. The pooled odds ratio was 0.65 (95% CI: 0.55-0.78; p<0.0001), indicating 35% lower odds of cessation among people who use cannabis. Between-study heterogeneity was high (I^2=88.1%; p<0.0001). Individual study estimates are represented by squares (proportional to study weight), with horizontal lines indicating 95% confidence intervals. The diamond represents the pooled effect estimate.

3.2 Endocannabinoid System Modulation of Nicotine-Related Behaviors: Preclinical Evidence

Fifteen preclinical studies examined cannabinoid system modulation of nicotine-related behaviors using rodent (n=16) and primate (n=1) models (**Table 1**). Paradigms included intravenous nicotine self-administration under fixed-ratio and progressive-ratio schedules, reinstatement models (cue-induced, nicotine-primed, contextual), conditioned place preference, and withdrawal assessment. Interventions were categorized by mechanism: CB1R antagonists/inverse agonists (n=6), CB1R agonists (n=2), CBD (n=1), and other endocannabinoid modulators (n=6).

3.2.1 Cannabinoid 1 Receptor Antagonists/Inverse Agonists

Six preclinical studies examined compounds that reduce CB1R signaling, including inverse agonists (AM251, rimonabant/SR141716A) and the neutral antagonist SLV330, demonstrating uniformly positive effects[30-35]. The inverse agonists—which not only block receptor activation but also suppress constitutive CB1R signaling—consistently reduced nicotine self-administration dose-dependently, with relative selectivity for nicotine over food reinforcement at lower doses[31]. Rimonabant additionally blocked nicotine-induced dopamine release in the nucleus accumbens shell and bed nucleus of the stria terminalis, providing mechanistic support for behavioral observations [30]. Regional specificity studies demonstrated that intra-VTA, but not intra-NAc, AM251 infusions attenuated self-administration, indicating modulation occurs primarily at midbrain dopaminergic cell bodies [35].

The neutral antagonist SLV330—developed to improve safety profiles by blocking agonist effects without suppressing baseline receptor activity—demonstrated comparable efficacy while additionally improving impulse control [33]. CB1R blockade also consistently

attenuated reinstatement, including context-induced renewal [32] and priming-induced reinstatement of conditioned place preference [34].

3.2.2 Cannabinoid 1 Receptor Agonists

Two preclinical studies examined CB1R agonists, revealing more complex and context-dependent effects[36,37]. The synthetic CB1/CB2 agonist WIN 55,212-2 produced schedule-dependent effects on nicotine self-administration: decreasing intake under fixed-ratio schedules but significantly increasing breakpoints under progressive-ratio schedules, indicating enhanced motivation for nicotine [37]. This apparent discrepancy likely reflects non-specific motor suppression when WIN 55,212-2 was co-administered with nicotine, as response rates were markedly reduced only during combined exposure.

Δ9-THC produced similarly complex results: post-session administration decreased nicotine intake during acquisition and maintenance, shifted dose-response curves downward, and delayed acquisition of stable self-administration [36]. However, these effects were timing-dependent and did not generalize to sucrose reinforcement, suggesting a specific nicotine-cannabinoid interaction rather than non-specific behavioral suppression.

3.2.3 Cannabidiol

A single study examined CBD and found that its administration dose-dependently decreased intravenous nicotine self-administration in mice at both low (0.03 mg/kg/infusion) and moderate (0.1 mg/kg/infusion) nicotine doses, with significant reductions observed at 40 and 100 mg/kg CBD [38]. Importantly, these effects were specific to nicotine reinforcement—CBD did not alter operant responding for food pellets, indicating the reduction in drug intake was not attributable to generalized motor suppression effects.

CBD also demonstrated efficacy across multiple withdrawal domains. Following chronic nicotine exposure via osmotic minipump, CBD (30-60 mg/kg) significantly attenuated somatic

withdrawal signs, reversed withdrawal-induced hyperalgesia, and ameliorated anxiety-like behavior in the light-dark box without affecting locomotor activity.

3.2.4 Indirect Cannabinoid System Modulation and Cannabinoid 2 Receptor Ligands

Six studies examined alternative approaches to cannabinoid system modulation, including fatty acid amide hydrolase (FAAH) inhibitors (2 studies)[39,40], anandamide transport inhibitors (2 studies)[41,42], selective CB2 receptor ligands (1 study)[43], and dual-mechanism compounds (1 study)[44]. These investigations reveal mechanism-specific dissociations between effects on nicotine-taking versus nicotine-seeking behavior.

FAAH inhibitors (URB597, URB694) and anandamide transport inhibitors (AM404, VDM11) consistently attenuated cue-induced and nicotine-primed reinstatement without affecting progressive-ratio break points or ongoing self-administration in rats [41-43]. In squirrel monkeys, FAAH inhibition shifted nicotine dose-response curves rightward and blocked reinstatement—effects reversed by the PPAR-α antagonist MK886, implicating non-cannabinoid fatty acid ethanolamides rather than anandamide-mediated CB1R activation[40].

Selective CB2 receptor modulation produced null effects: neither the agonist AM1241 nor antagonist AM630 affected nicotine self-administration or reinstatement[43].

Δ8-tetrahydrocannabivarin— which combines CB1R antagonist and CB2R agonist properties—demonstrated comprehensive efficacy, attenuating self-administration, cue- and nicotine-primed reinstatement, conditioned place preference acquisition, and all three withdrawal measures (anxiety-like behavior, somatic signs, hyperalgesia) without producing conditioned place preference or aversion[44].

Collectively, the preclinical evidence identifies CB1R antagonism and endocannabinoid tone modulation as viable targets for reducing nicotine reinforcement and relapse. Direct CB1R agonism produces complex, context-dependent effects—reducing intake under some conditions but enhancing motivation under others—a pattern that cautions against extrapolating from

naturalistic cannabis exposure to therapeutic expectations. CBD demonstrates efficacy across both self-administration and withdrawal domains without the mechanistic liabilities of either antagonism or agonism, positioning it as a candidate warranting clinical translation.

3.3 Endocannabinoid System Modulation of Nicotine-Related Behaviors: Clinical Evidence

Nineteen human studies examined endocannabinoid system modulation for nicotine addiction, comprising a pooled analysis and individual trials of CB1R inverse agonists (rimonabant, surinabant, taranabant) and six studies of CBD. These investigations employed diverse methodological approaches including randomized controlled trials (parallel-group and crossover), and open-label studies (**Table 2**).

3.3.1 Cannabinoid 1 Receptor Inverse Agonists

Three CB1R inverse agonists—rimonabant, surinabant, and taranabant—underwent clinical evaluation for smoking cessation. A pooled analysis of three rimonabant trials[45] (STRATUS EU, US, META; N=2,097) found that, at 8-week end-of-treatment, rimonabant 20 mg demonstrated significantly higher prolonged abstinence versus placebo: 21.6% versus 14.7% (OR = 1.61; 95% CI: 1.24, 2.08; $p = 0.0004$). This advantage persisted at 48-week follow-up: 14.8% versus 10.4% (OR = 1.50; 95% CI: 1.03, 2.17; $p = 0.04$). The 5 mg dose showed no superiority (OR = 1.05; $p = 0.81$). The adverse event profile revealed clinically significant concerns: overall events occurred in 69.6% versus 61.0% of placebo recipients, driven by gastrointestinal symptoms and psychiatric manifestations (anxiety: 9.8% vs. 5.7%). Treatment discontinuation rates doubled with rimonabant (11.0% vs. 5.6%; $p < 0.001$), and post-marketing surveillance ultimately identified serious psychiatric risks including depression and suicidality, leading to market withdrawal in 2008.

A randomized-controlled trial evaluated surinabant (2.5-10 mg/day) in 810 participants over 8 weeks[46]. Four-week continuous abstinence rates showed no dose-response: 22.6%, 22.1%, 21.5% for 2.5, 5, 10 mg versus 25.2% placebo (p trend = 0.40). Surinabant produced dose-dependent weight suppression (0.24-0.75 kg vs. 1.19 kg placebo; $p < 0.001$) and increased psychiatric (43.4% vs. 26.6%), gastrointestinal (49.7% vs. 19.0%), and vasomotor adverse events (10.7% vs. 1.9%). Similarly, taranabant (2-8 mg/day titration; N=317) failed to achieve efficacy[47], with continuous abstinence rates of 7.5% versus 6.3% placebo (OR = 1.2; p = 0.678) despite producing significant weight loss and reduced cigarette consumption among non-abstainers.

3.3.2 Cannabidiol

Four studies evaluated CBD for TUD using diverse methodologies. A double-blind, placebo-controlled crossover trial in 24 daily tobacco smokers (≥10 cigarettes/day) examined CBD inhaler (400 µg/actuation) versus placebo for one week with ad libitum use[48]. The CBD group demonstrated 40% reduction in cigarette consumption (baseline 18.2/day reduced ~9 cigarettes; p = 0.002), maintained at 2-week follow-up (p = 0.034). Craving scores (Tiffany Craving Questionnaire) did not differ between groups.

A subsequent crossover study examined single-dose oral CBD 800 mg effects in 30 overnight-abstinent smokers across multiple cognitive and motivational domains[49,50]. Attentional bias assessment using a visual probe task revealed that placebo-treated abstinent tobacco smokers showed marked bias toward cigarette cues at 200 ms exposure (p = 0.001; d = 0.789). CBD reversed this effect such that bias no longer differed from satiated baseline (p = 0.82). CBD reduced explicit pleasantness ratings of cigarette images (p = 0.011; d = 0.514) but did not affect self-reported craving or withdrawal symptoms. Cognitive performance assessments revealed null effects on delay discounting (p = 0.801), prose recall (p = 0.244), and n-back tasks (p = 0.472).

Most recently, an open-label crossover study evaluated CBD 320 mg for e-cigarette cessation in 20 individuals who use tobacco daily experiencing anxiety during withdrawal[51]. Following 4-hour supervised abstinence, CBD significantly reduced withdrawal severity (MTWS-R: 6.5 vs. 12.0; $p < 0.001$; $d = 0.704$) and state anxiety (STAI-S: 37.0 vs. 48.0; $p < 0.001$; d=0.514), with large effect sizes. Effects remained significant after controlling for expectancies. CBD was well-tolerated with mild adverse events (somnolence, nausea, headache) in 4 participants.

3.3.3 Human Experimental Evidence on Tobacco-Cannabis Interactions

A separate body of human experimental research has examined how cannabis and tobacco interact when co-used. We organized this literature into three domains: acute behavioral interactions, cognitive and affective mechanisms, and clinical implications for withdrawal and relapse.

3.3.3.1 Acute Behavioral and Subjective Effects

Human experimental research examining whether cannabis use acutely alters tobacco smoking behavior ("chasing") has produced mixed results. A residential study found that active cannabis smoking significantly decreased the number of daily tobacco smoking bouts but increased the intensity of smoking within bouts (decreased inter-puff intervals)[52]. However, subsequent laboratory studies have generally not supported a strong pharmacological drive for this behavior. Various doses of active cannabis produced no reliable changes in the number of tobacco cigarettes smoked or smoking topography compared to placebo[53]. Similarly, a study on daily people who co-use both substances found that smoking active cannabis did not significantly alter tobacco cigarette craving or puff topography (e.g., puff volume, velocity) compared to placebo, suggesting that the "chasing" phenomenon may be driven more by learning or environmental cues than direct pharmacological interaction[54].

Regarding subjective and physiological effects, nicotine appears to enhance certain responses to cannabis. Pretreatment with a 21-mg transdermal nicotine patch significantly enhanced cannabis-induced increases in heart rate and subjective ratings of stimulation, particularly in male participants[55]. Conversely, regarding the potential for acute cannabis intoxication to act as a "gateway" via motivational changes, a study found that while cannabis intoxication reduced motivation for cannabis (satiation), it did not increase implicit or explicit motivation for tobacco[56].

3.3.3.2 Cognitive and Affective Effects

Human experimental data on interactions between nicotine and cannabinoids also extend to cognitive performance and affective regulation. In a placebo-controlled crossover trial among non-dependent co-users, tobacco co-administration offset some cannabis-induced cognitive deficits, improving working memory performance independently of cannabis and mitigating impairments in delayed verbal recall[57]. However, a companion analysis from the same sample examining reward processing found that tobacco did not influence the rewarding effects of cannabis (demand or liking) or craving[58], suggesting the drugs may have independent rather than synergistic effects on reward valuation.

In terms of stress and affect, a study observed that during nicotine withdrawal, people who co-use nicotine and cannabis exhibited blunted cortisol and blood pressure responses to acute stress compared to people who do not co-use, yet reported higher levels of cannabis craving[59], indicating a complex dysregulation of stress systems in people who co-use.

3.3.3.3 Clinical Tobacco Use Disorder Outcomes

A within-subject study compared withdrawal from cannabis, tobacco, and both substances simultaneously. Simultaneous withdrawal produced more severe anger and

aggression than withdrawal from either substance alone, while the overall magnitude of cannabis-only withdrawal was comparable to tobacco-only withdrawal[60].

Two human laboratory studies examined tobacco smoking status as a predictor of return to using cannabis. Daily cannabis smokers who also smoked cigarettes were more likely to relapse to cannabis use during a laboratory abstinence phase than those who did not smoke cigarettes[61]. Acute tobacco abstinence did not alter cannabis relapse rates compared to smoking as usual[61].

A secondary analysis of a multi-site, double-blind, laboratory study found that cannabis use status did not moderate the effects of reduced nicotine content cigarettes (RNCC); people who use cannabis and those who do not responded similarly to RNCCs in terms of reduced reinforcement and withdrawal suppression, suggesting that policy-level interventions reducing nicotine content may be equitable across cannabis-using and non-using populations[62].

4. Discussion

This translational systematic review and meta-analysis synthesized observational, preclinical, and human experimental evidence addressing two complementary questions: whether naturalistic cannabis co-use is associated with smoking cessation outcomes, and whether targeted ECS modulation offers therapeutic potential for TUD.

Our main findings are: (1) cannabis use is associated with 35% reduced odds of smoking cessation; (2) CB1R antagonists show robust preclinical efficacy but failed clinically due to psychiatric adverse effects; (3) CBD emerges as a promising alternative with favorable mechanistic effects and safety; and (4) co-use interaction studies suggest bidirectional withdrawal and reinforcement dynamics that contextualize the observational association. Collectively, these findings have methodological, clinical, and mechanistic implications for

tobacco treatment and for ECS-targeted therapeutic development in an era of expanding cannabis availability.

4.1. Implications to Understand Tobacco and Cannabis Co-Use Patterns and Cessation

The 35% reduction in cessation odds among people who use cannabis (OR=0.65; 95% CI: 0.55-0.78) represents a clinically meaningful effect, particularly as co-use prevalence rises. The magnitude of this association exceeds that of several established negative prognostic factors in large cessation trials, including anxiety disorder (OR=0.71), psychotic disorder (OR=0.73), and prior failed pharmacotherapy attempts (OR=0.78)[63], supporting routine assessment of cannabis use status alongside these risk markers in cessation treatment planning.

At the population level, cannabis-tobacco co-use has increased steadily—rising from approximately 4.4% to 6.2% between 2002 and 2019—and has remained elevated through 2023[64,65]. If the association identified here remains stable as co-use prevalence increases, the population-attributable impact on tobacco control may grow correspondingly—particularly given that people who co-use often present with greater dependence severity and more failed quit attempts at baseline[14,15].

Methodologically, this pooled observational association should be interpreted as robust but not causal. Observational designs cannot fully adjudicate directionality (e.g., whether cannabis use directly impairs cessation versus marking a higher-risk phenotype), and residual confounding by impulsivity, psychiatric comorbidity, social environment, and polysubstance exposure likely contributes. However, the consistency of associations across extensively adjusted studies suggests confounding does not fully explain the signal. Key sources of heterogeneity that future work should standardize include cannabis exposure definitions (frequency, product type/ Δ9-THC content, route), timing relative to the quit attempt, and cessation outcome definitions (point prevalence vs continuous abstinence; biochemical

verification; follow-up duration). These measurement choices map onto distinct mechanistic hypotheses (reinforcement potentiation vs withdrawal coupling vs conditioned co-administration).

Mechanistically, several pathways plausibly link co-use to cessation difficulty. Preclinical evidence indicates that prior Δ9-THC exposure can enhance nicotine reinforcement[66], raising the possibility that some people who co-use experience potentiated nicotine reward and higher dependence severity. Co-use interaction studies further suggest that dual abstinence may amplify withdrawal[60] and that nicotine dependence can heighten cannabis withdrawal severity[67]—creating bidirectional vulnerability where attempts to quit tobacco may precipitate increased cannabis use (and vice versa). Co-administration (including within the same product) may also create conditioned associations that trigger relapse to either drug[12]. Together, these data support clinical approaches that explicitly assess co-use patterns, anticipate withdrawal coupling, and consider integrated intervention strategies.

Clinically, the findings support routine cannabis use assessment in individuals presenting for tobacco treatment. People who co-use may benefit from intensified behavioral support, closer monitoring during quit attempts, and treatment plans that anticipate bidirectional craving/withdrawal dynamics. Whether efficacy of standard cessation medications differs by cannabis use status—and whether targeted adaptations improve outcomes—remains a critical priority for prospective research.

4.2 Implications to Understand Why Cannabinoid 1 Receptor Antagonists Failed and What Comes Next

The translational question—whether targeted ECS modulation can benefit tobacco use disorder—yields a more complex picture. Preclinical evidence robustly supports CB1R antagonism: all six studies reported favorable effects, often with regional specificity (e.g., VTA-selective action) and mechanistic confirmation (e.g., blockade of nicotine-induced dopamine

release). Yet clinical translation failed decisively. Both taranabant and surinabant showed no cessation efficacy despite evidence of biological activity (e.g., weight effects), and both increased psychiatric adverse events, suggesting a mechanism-linked limitation rather than an idiosyncratic compound failure.

Several mechanistic factors likely contribute to this translational disconnect. First, doses tolerated in humans may produce only partial CB1R occupancy, whereas preclinical efficacy is often observed under near-complete functional blockade; escalation is constrained by dose-dependent psychiatric toxicity, creating a practical therapeutic-window problem. Second, psychiatric adverse effects may relate specifically to inverse agonism (suppression of constitutive CB1R activity) rather than simple competitive antagonism, raising the possibility that neutral antagonists could retain efficacy with improved tolerability. Third, clinical trials rely on chronic daily dosing over weeks, whereas many animal studies examine acute pre-treatment effects; chronic exposure may permit neuroadaptations that attenuate efficacy or alter behavioral endpoints.

Against this backdrop, CBD emerges as the most promising candidate among clinically tractable ECS-related approaches. The 40% reduction in cigarette consumption observed by Morgan and colleagues offers preliminary proof-of-concept[48], though replication in adequately powered, rigorously controlled trials is needed. Mechanistic plausibility is supported by evidence that CBD reduces cue salience and pleasantness[49], potentially disrupting automatic approach responses that maintain habitual smoking. Importantly, CBD does not act as a straightforward CB1R blocker; its pleiotropic pharmacology—including negative allosteric modulation, 5-HT1A agonism, TRPV1 activation, and endocannabinoid tone modulation[68]—may allow indirect ECS modulation without the depressive/anxiogenic liabilities observed with CB1R inverse agonists. This profile preserves baseline signaling while potentially dampening pathological reward processing that sustains addiction, consistent with its favorable safety record and prioritization for larger cessation trials.

Methodologically, advancing CBD (and related tone-modulating approaches) will require careful attention to product characterization (composition/contaminants), dose selection anchored in exposure-response, and endpoint selection that aligns with mechanism (e.g., cue reactivity, reinforcement, withdrawal coupling), ideally alongside biochemical verification of tobacco and cannabis use.

4.3. Naturalistic Cannabis Exposure vs. Targeted Endocannabinoid System Modulation: Bridging the Translational Gap

An apparent paradox emerges: cannabis co-use is associated with worse cessation outcomes, yet some cannabinoid-based pharmacotherapies show promise (**Figure 3**). This paradox resolves when distinguishing naturalistic exposure from targeted pharmacological intervention. Recreational cannabis typically delivers Δ9-THC, a CB1R partial agonist that can enhance nicotine reinforcement in preclinical models[66], and is self-administered in contexts tightly linked to tobacco use—reinforcing conditioned associations. People who co-use may also experience compounded withdrawal, bidirectional craving, and psychosocial correlates of polysubstance use[11,12,15,60,67] that magnify relapse risk.

In contrast, pharmacotherapy aims to engage specific ECS components to modify addiction-relevant processes without intoxication or reinforcing context. Targeted agents can be selected for distinct mechanistic profiles that address two relapse drivers: positive reinforcement (e.g., dampening cue-induced seeking without Δ9-THC-like reward signaling) and negative reinforcement (e.g., reducing anxiety, discomfort, or hyperalgesia that escalates craving). For example, FAAH inhibition elevates endogenous fatty acid ethanolamides and can attenuate reinstatement-like behaviors without necessarily reducing ongoing self-administration in some paradigms[39,40], consistent with a mechanism that preferentially impacts cue-triggered relapse vulnerability. CBD's pleiotropic effects may similarly reduce cue salience and withdrawal-related

affective dysregulation, with emerging evidence suggesting potential effects on pain sensitivity and stress responsivity[38,51].

Clinically, this distinction matters in both directions. The observational findings should not deter development of ECS-targeted cessation pharmacotherapies: the relevant question is not whether "cannabis" helps or harms quitting, but whether specific ECS mechanisms can be therapeutically leveraged. Conversely, CBD's promise should not be conflated with endorsing cannabis use during quit attempts—particularly Δ9-THC-dominant products that may potentiate nicotine reinforcement and strengthen conditioned co-use. The endocannabinoid-nicotinic interface therefore represents both a clinical challenge and a therapeutic opportunity: similar circuitry can yield divergent outcomes depending on pharmacodynamics (multi-component exposure from cannabis vs. predominant CB1R agonism vs. other forms of ECS modulation, dosing control), pharmacokinetics (route of administration, rate of delivery) and behavioral context (**Figure 3**).

Figure 3. The Translational Disconnect: Naturalistic Cannabis Co-Use vs. Targeted Cannabinoid Modulation in Nicotine Dependence



Conceptual framework contrasting two pathways through which the endocannabinoid system intersects with nicotine dependence. Panel (A) illustrates how naturalistic cannabis-tobacco co-use may impair cessation through cross-sensitization, conditioned associative learning, and bidirectional withdrawal amplification. Panel (B) depicts how targeted pharmacological modulation of the endocannabinoid system may offer therapeutic benefit by reducing cue salience, restoring endocannabinoid tone, and mitigating negative affect during withdrawal.

4.4 Limitations

Several limitations warrant consideration. First, high heterogeneity ($I^2 = 88.1\%$) was observed across studies, likely reflecting differences in cannabis use definitions, cessation outcome measures, follow-up durations, and abstinence verification methods. Furthermore, this heterogeneity captures the clinical diversity of the included studies, which applied different interventions (ranging from pharmacotherapy to digital health tools), targeted distinct populations (e.g., adolescents, adults with diabetes), and included varied nicotine products (combustible cigarettes vs. e-cigarettes). Second, although formal publication bias tests (Egger's $p = 0.071$; Begg's $p = 0.948$) were non-significant, selective reporting of positive findings cannot be excluded. Third, observational designs preclude causal inference, as unmeasured confounders—including psychiatric comorbidity, polysubstance use, and nicotine dependence severity—may partially account for the observed association. Fourth, most included studies did not biochemically verify cannabis use or smoking abstinence, introducing potential misclassification bias.

4.5 Future Directions

First, adequately powered randomized trials of CBD for smoking cessation are needed, examining dose-response relationships, optimal formulations, and treatment duration. Second, neutral CB1R antagonists and FAAH inhibitors merit clinical development given consistent preclinical efficacy and mechanistic distinctiveness from failed inverse agonists. Third, the impact of co-use on standard cessation pharmacotherapy efficacy requires prospective

investigation; if co-users respond differentially to varenicline or NRT, tailored algorithms may be warranted. Fourth, integrated interventions addressing both tobacco and cannabis should be developed for co-users, given bidirectional withdrawal dynamics. Fifth, biomarker-driven patient stratification using endocannabinoid levels, CB1R availability imaging, or genetic polymorphisms may identify individuals most likely to respond to cannabinoid-based treatments.

5. Conclusions

In this translational systematic review and meta-analysis, we have highlighted the endocannabinoid-nicotinic interface as both a clinical challenge and therapeutic frontier. Cannabis co-use—now prevalent in over 20% persons who use tobacco and rising with legalization—is associated with 35% lower odds of cessation success, underscoring the need for routine co-use assessment and potentially intensified intervention for affected individuals. Simultaneously, targeted pharmacological modulation of the ECS shows mechanistic promise, particularly through CBD-rich formulations that avoid the rapid reinforcement dynamics of smoked, Δ9-THC-dominant products and the psychiatric adverse effects of CB1R inverse agonists. The distinction between naturalistic cannabinoid exposure and potentially beneficial targeted pharmacotherapy resolves the apparent paradox of these findings and has direct implications for both clinical practice and therapeutic development. As cannabis access expands, attention to this neurobiological intersection becomes increasingly urgent for tobacco control efforts.

Table 1. Preclinical Studies

Study	Objective	Species/Strain	Compound (Dose)	Administration Method	Effect	Key Findings
CB1R Antagonists/Inverse Agonists						
Shoaib 2008	To evaluate the effects of the CB1 antagonist AM251 on nicotine SA and reinstatement of nicotine-seeking behavior.	Male hooded Lister rats	AM251 (1-10 mg/kg)	IV Self-administration (FR); Reinstatement	**Positive**	Dose-dependent suppression of nicotine self-administration (1, 3, and 10 mg/kg). Attenuated reinstatement induced by the combination of nicotine priming and cues. Effects were relatively selective for nicotine over food at lower doses.
de Bruin 2011	To investigate whether the CB1 antagonist SLV330 could reduce ethanol and nicotine self-administration and cue-induced reinstatement, and improve inhibitory response control.	Male Wistar rats	SLV330 (1-10 mg/kg)	IV Self-administration; Cue-induced Reinstatement	**Positive**	Reduced nicotine self-administration (LED 10 mg/kg) and significantly suppressed cue-induced reinstatement of nicotine seeking (LED 10 mg/kg). Also improved impulse control in the 5-CSRTT.
Diergaarde 2008	To determine whether context re-exposure reinstates nicotine seeking (renewal) and if Rimonabant (SR141716A) attenuates this effect.	Male Wistar rats	SR141716A (Rimonabant) (1-3 mg/kg)	Contextual Renewal (IVSA extinction & reinstatement)	**Positive**	Dose-dependently attenuated context-induced renewal of nicotine seeking when rats were re-exposed to the self-administration environment. Did not affect responding in the extinction context (control group).
Simonnet 2013	To determine whether central injections of the CB1 receptor antagonist AM251 into the VTA or NAC alter nicotine IVSA.	Male Sprague Dawley rats	AM251 (0.1-10 µg/side)	Intra-cranial infusion (VTA and NAc) during IVSA	**Positive**	Intra-VTA infusions dose-dependently reduced nicotine self-administration, with significant decreases at 10 µg. Intra-NAc infusions had no effect on nicotine intake. Water self-administration was unaltered by intra-VTA infusion.
Cohen 2002	To evaluate the effects of SR141716 on the motivational effects (SA), discriminative	Male Sprague-Dawley rats	SR141716 (Rimonabant) (0.03-1 mg/kg)	IV Self-administration; Drug Discrimination; Microdialysis	**Positive**	Decreased nicotine self-administration (0.3 and 1 mg/kg). Antagonized substitution of nicotine for D-

	stimulus effects, and dopamine-releasing effects of nicotine.					amphetamine. Blocked nicotine-induced dopamine release in the NAc shell and bed nucleus of the stria terminalis.
Budzyńska 2009	To evaluate the role of CB1 receptors in the reinstatement of nicotine-induced conditioned place preference.	Male Wistar rats	AM 251 (0.25-0.5 mg/kg)	Conditioned Place Preference (CPP) Reinstatement	**Positive**	Dose-dependently attenuated the reinstatement of nicotine-induced conditioned place preference triggered by a priming dose of nicotine. Significant effect at 0.5 mg/kg, but not 0.25 mg/kg.
CB1R Agonists						
Gamaleddin 2012a	To investigate the effects of the CB1/2 agonist WIN 55,212-2 on nicotine self-administration (FR/PR) and reinstatement.	Male Long Evans rats	WIN 55,212-2 (0.1-1 mg/kg)	IV Self-administration (FR & PR); Reinstatement	**Negative**	Decreased intake on FR schedule (likely non-specific) but increased motivation (breakpoint) on PR schedule. Induced reinstatement of nicotine seeking and potentiated cue-induced reinstatement.
Abraham 2023	To examine the effects of co-administration of nicotine and Δ9-THC (experimenter-administered) on acquisition and maintenance of nicotine SA.	Male and Female Sprague-Dawley rats	Δ9-THC (3, 30 mg/kg chronic; 0.3-30 mg/kg acute)	IV Self-administration (Acquisition & Dose-response)	**Mixed**	Chronic post-session Δ9-THC decreased acquisition and maintenance of nicotine self-administration in both sexes. However, acute pre-session low-dose Δ9-THC (0.3 mg/kg) increased nicotine intake in males.
Endocannabinoid Modulators (Transport/Enzyme Inhibitors)						
Gamaleddin 2011	To investigate the effects of the selective anandamide transport inhibitor VDM11 on nicotine SA and cue-induced reinstatement.	Male Long Evans rats	VDM11 (1-10 mg/kg)	IV Self-administration; Reinstatement	**Mixed**	Dose-dependently attenuated reinstatement induced by cues and nicotine priming. Did not affect stable nicotine self-administration under Fixed Ratio or Progressive Ratio schedules.
Gamaleddin 2013	To assess the effects of the anandamide transport inhibitor AM404 on nicotine-taking and reinstatement	Male Long Evans rats	AM404 (1-10 mg/kg)	IV Self-administration; Reinstatement; CPP	**Mixed**	Dose-dependently attenuated reinstatement induced by nicotine-associated cues and nicotine priming. Did not modify nicotine-taking behavior (FR

	of nicotine seeking.					or PR) or food-taking behavior, and did not produce CPP.
Justinova 2015	To study the effects of first (URB597) and second (URB694) generation FAAH inhibitors on nicotine reward and relapse in non-human primates.	Male Squirrel Monkeys	FAAH inhibitors (URB597, URB694)	IV Self-administration; Reinstatement	**Positive**	Both FAAH inhibitors shifted nicotine dose-response curves (reduced reward) and blocked reinstatement induced by priming or cues. Effects were reversed by PPAR-α antagonist MK886. URB694 was self-administered at moderate rates, unlike URB597.
Forget 2009	To explore the effect of inhibiting FAAH enzyme by URB597 on nicotine SA (PR) and reinstatement, compared with Rimonabant.	Male Long-Evans rats	URB597 (FAAH inhibitor) (0.3-1 mg/kg)	IV Self-administration (PR); Reinstatement	**Mixed**	Reduced reinstatement of nicotine seeking induced by cues or priming. However, unlike Rimonabant, URB597 did not reduce the break point for nicotine self-administration under a progressive ratio schedule.
Other Cannabinoid Compounds / Dual Action						
Xi 2019	To determine if Δ8-THCV inhibits nicotine SA, reinstatement, and withdrawal-induced anxiety.	Male P rats; Male ICR mice	Δ8-THCV (3-20 mg/kg)	IV Self-administration; Reinstatement; CPP; Withdrawal	**Positive**	Significantly reduced nicotine self-administration, cue-induced seeking, and nicotine-triggered reinstatement. Attenuated nicotine-induced CPP and somatic/affective withdrawal signs.
Gamaleddin 2012b	To investigate the effects of selective CB2 receptor modulation on nicotine self-administration and reinstatement.	Male Long Evans rats	AM1241 (CB2 agonist); AM630 (antagonist)	IV Self-administration; Reinstatement	**Neutral**	Neither the selective CB2 agonist (AM1241) nor the selective CB2 antagonist (AM630) affected nicotine self-administration (FR or PR) or reinstatement induced by cues or priming. Suggests CB2 receptors may not be involved in these specific nicotine behaviors.
Cheeks 2024	To examine whether orally dosed CBD would alter nicotine self-administration and mitigate somatic	M & F C57BL/6J mice	Cannabidiol (CBD) (40-100 mg/kg)	IV Self-administration; Withdrawal	**Positive**	Acute oral CBD decreased nicotine intake at both low and moderate nicotine doses. Attenuated somatic signs of withdrawal

	withdrawal symptomology.					and prevented withdrawal-induced hyperalgesia. Had no effect on food self-administration.

Table 2. Human Experimental Studies

Study	Study Design	Sample	Intervention	Performance/Behavioral Effects	Subjective Effects	Overall Effect on Tobacco-Related Behaviors
Cannabidiol (CBD) Interventions						
Morgan et al. (2013)	Pilot RCT; double-blind; ad libitum use (1 week)	24 smokers wishing to quit (>10 cigs/day)	CBD inhaler (400µg/dose) vs. Placebo; ad-libitum use	Consumption: CBD group reduced cigarettes smoked by ~40% (p=.002); Placebo group showed no change	Craving: No significant difference in craving between groups Anxiety: Both groups showed reduced anxiety over time (p=.04)	Positive (Significant reduction in consumption without increased craving)
Hindochaet al. (2018) [Addiction]	Laboratory; double-blind crossover; visual probe task (attentional bias)	30 dependent cigarette smokers (abstinent overnight)	800mg Oral CBD vs. Placebo	Attentional Bias: CBD reversed bias away from cues vs. placebo (p=0.007, d=0.704). Bias under CBD did not differ from satiated state (p=.82)	Pleasantness: CBD reduced explicit pleasantness of cigarette images (p=.011, d=0.514) Craving: CBD did not affect craving or withdrawal.	Positive (Reduces salience/pleasantness of cues, though not craving)
Hindocha et al. (2018) [Sci Rep]	Laboratory; double-blind crossover; cognitive tasks	30 dependent cigarette smokers (abstinent overnight)	800mg Oral CBD vs. Placebo	Impulsivity: No effect on delay discounting (p=.801); Errors: CBD increased commission errors on Go/No-Go (p=.03); Memory: No effect on prose recall (p=.244)	Not reported	Neutral (No cognitive improvement during withdrawal)
Gournay et al. (2024)	Open-label crossover; acute abstinence (4 hours)	20 daily e-cigarette users	320mg Oral CBD vs. No CBD	Not reported	Withdrawal: CBD significantly reduced withdrawal severity (M=6.5) vs. No CBD (M=12) (p<.001); Anxiety: CBD reduced state anxiety (M=37.0) vs. No CBD	Positive (Reduces acute withdrawal severity and anxiety)

					(M=48.0) (p<0.001)	
CB1 Receptor Antagonists / Inverse Agonists						
Robinson et al. (2017)	Pooled analysis of 3 RCTs (STRATUS EU, US, META); double-blind, placebo-controlled; 10-week treatment + 40-week follow-up (EU/US only)	2,097 smokers motivated to quit (>9 cigs/day)	Rimonabant (CB1 inverse agonist) 20mg or 5mg vs. Placebo	Abstinence (EOT): 20mg significantly higher than placebo (SRNT prolonged: OR=1.61, 95% CI: 1.24-2.09; FDA continuous: OR=1.66, 95% CI: 1.23-2.23); 5mg did not differ from placebo. Abstinence (48 weeks): 20mg superior to placebo (OR=1.50, 95% CI: 1.03-2.17). Weight: 20mg reduced weight gain at EOT (-0.01 kg vs. +1.76 kg placebo, p<.0001); no difference at 48 weeks.	HADS: No significant difference in depression or anxiety change scores between groups.	Positive (Modest but significant efficacy for cessation at EOT and 48 weeks; weight benefit during treatment only; notable GI and anxiety-related adverse events)
Morrison et al. (2010)	Outpatient RCT; 8-week treatment; safety and efficacy	317 chronic smokers (>10 cigs/day)	Taranabant (CB1 inverse agonist) titrated 2-8mg vs. Placebo	Abstinence: No difference in continuous abstinence (7.5% Taranabant vs 6.3% Placebo; OR=1.2, p=.678) Weight: Taranabant group lost weight (-1.6kg) vs Placebo gain (+0.6kg) (p<.001)	Adverse Events: Higher incidence of psychiatric events (43.4% vs 26.6%, p=.002) and GI events (49.7% vs 19.0%, p<.001) in Taranabant group	Negative (Ineffective for cessation; significant adverse side effects)
Tonstad & Aubin (2012)	Outpatient RCT; 8-week treatment; dose-ranging	810 smokers (>10 cigs/day)	Surinabant (CB1 antagonist) 2.5, 5, or 10mg vs. Placebo	Abstinence: No difference in 4-week abstinence (21.5-22.6% Surinabant vs 25.2% Placebo; p=0.4); Weight: Dose-dependent reduction in gain (0.24kg for 10mg vs 1.19kg Placebo; p<.001)	Adverse Events: Higher incidence of anxiety (7.5-9.8% vs 7.5%) and depression (3.5-5.9% vs 4.0%) in active groups	Neutral (Ineffective for cessation; positive effect on weight)

					compared to placebo	
Acute Δ9-THC/Cannabis Effects on Tobacco Smoking						
Kelly et al. (1990)	Residential laboratory; 10-15 day isolation; within-subjects	8 male heavy smokers	Smoked cannabis (0%, 1.3%, 2.3%, or 2.7% Δ9-THC) 4x/day	Topography: Active cannabis significantly decreased tobacco smoking bouts (p<.05); Timing: Increased interval between cannabis use and next cigarette (p<.005)	Not primary focus	Positive (Acute cannabis suppressed tobacco smoking frequency)
Nemeth-Coslett et al. (1986)	Laboratory; controlled acute administration; within-subjects	8 heavy smokers (30 cigs/day)	Smoked cannabis (0%, 1.3%, 2.8%, 4.0% Δ9-THC)	Topography: No significant alteration in number of cigarettes or puff duration following cannabis smoking	Ratings: Cannabis increased "drug effect" ratings (p<.001) but did not alter subjective ratings of tobacco cigarettes	Neutral (No effect on tobacco smoking behavior)
Peters et al. (2021)	Laboratory; double-blind crossover; ad libitum smoking task	9 daily cannabis and tobacco co-users	Smoked Cannabis (5.2% Δ9-THC) vs. Placebo	Topography: No significant difference in total puff volume (p=.21), duration (p=.86), or velocity (p=.11)	Subjective: No significant difference in tobacco craving or subjective effects (e.g., "liking") after adjusting for baseline levels	Neutral (No uniform effect on tobacco intensity or subjective reward)
Gorey et al. (2024)	Naturalistic (Coffeeshop); double-blind crossover; implicit association	85 light users of cannabis/tobacco	Smoked joint (Δ9-THC vs. Placebo)	Implicit Bias: No effect of cannabis on approach/avoidance bias for tobacco (p=.21); Behavior: Baseline motivation did not predict use at 6-month follow-up (p=.94)	Avoidance: Explicit tobacco avoidance decreased in *both* active (p<.001) and placebo (p<.001) conditions	Neutral (No pharmacological "gateway" effect; setting reduces avoidance)
Co-Use Interactions (Mechanisms, Withdrawal & Relapse)						
Herrmann et al. (2019)	Laboratory + Inpatient; double-blind; relapse model	46 tobacco/cannabis co-users	Outpatient: Varenicline vs. Placebo; Inpatient: Nabilone vs. Placebo	Tobacco: Varenicline increased tobacco abstinence rates (46% vs 24%, p=.001); Cannabis: Nabilone did not	Withdrawal: Nabilone attenuated cannabis withdrawal (e.g., irritability	Mixed (Varenicline helped tobacco cessation; Nabilone helped withdrawal but

				reduce cannabis relapse inhalations (p>.05)	p<.05); Craving: Varenicline reduced cigarette craving (p<.05)	not cannabis relapse)
Hindocha et al. (2017a) [Psych Med]	Laboratory; double-blind crossover; memory tasks	24 non-dependent co-users	Cannabis (Active/Placebo) + Tobacco (Active/Placebo) in joints	Memory: Tobacco offset cannabis-induced impairment in delayed recall (p=.037, d=0.5); Working Memory: Tobacco improved correct responses (p=.037)	Psychotomimetic: Tobacco did not alter ratings of "stoned," "dizzy," or PSI scores induced by cannabis (p>.05)	Interaction (Tobacco mitigates some cannabis-induced cognitive deficits)
Hindocha et al. (2017b) [Psychopharm]	Laboratory; double-blind crossover; purchase tasks	24 non-dependent co-users	Cannabis (Active/Placebo) + Tobacco (Active/Placebo) in joints	Demand: Active cannabis reduced cigarette breakpoint (p=.01); Response Time: Cannabis slowed RT to all stimuli except cigarette cues (p=.02)	Liking: Cannabis reduced liking of cannabis stimuli (p=.01); Tobacco had no effect on liking/craving (p>.05)	Interaction (Acute cannabis reduced motivation/demand for tobacco; Tobacco did not increase cannabis reward)
Penetar et al. (2005)	Laboratory; double-blind crossover; acute administration	20 smokers (10M/10F)	Transdermal Nicotine (21mg) + Smoked Cannabis (2% or 3.5% Δ9-THC)	Physiological: Nicotine enhanced cannabis-induced heart rate increases (Mean increase 58 vs 45 bpm; p<.001)	Subjective: Nicotine enhanced "Stimulated" ratings and ARCI Amphetamine scale after cannabis (p=.01)	Synergistic (Nicotine enhances physiological and stimulant effects of cannabis)
Vandrey et al. (2008)	Within-subject ABACAD design; 5-day abstinence periods	12 heavy co-users	Abstinence from: Cannabis, Tobacco, or Both	Not applicable	Withdrawal: Dual abstinence scores (e.g., aggression) higher than single on Day 2; Discomfort: Varied preference (5 rated dual hardest, 5 rated dual easiest)	Negative (Dual abstinence can increase withdrawal severity, though not uniformly)
al'Absi et al. (2024)	Laboratory; stress reactivity task	79 participants (Nicotine only, Cannabis only, Co-users, Non-users)	15h Nicotine abstinence vs. Ad libitum use	BP/HR: Nicotine users showed blunted systolic BP response; Cannabis users showed exaggerated	Craving: Co-users had higher cannabis craving than cannabis-only users (p<.01);	Negative (Nicotine withdrawal in co-users may heighten cannabis craving and

				diastolic BP (p=.03)	Affect: Nicotine users reported less positive affect (p<.05)	alter stress response)
Haney et al. (2013)	Inpatient; within-subject crossover (Study 2)	15 daily cannabis/cigarette smokers	Smoking As Usual (SAU) vs. Tobacco Quit (abstinence)	Relapse: Tobacco status did not influence cannabis relapse (93% SAU vs 87% Quit relapsed; number of puffs identical)	Withdrawal: Tobacco status did not alter cannabis intoxication or withdrawal symptoms (p>.05)	Null (Acute tobacco abstinence does not improve cannabis relapse outcomes)
Parker et al. (2018)	Laboratory; double-blind crossover; reduced nicotine cigarettes (RNCC)	169 vulnerable smokers (63 cannabis users)	RNCCs (0.4 to 15.8 mg/g nicotine)	Reinforcement: Cannabis use status did not moderate nicotine dose effect on choice (p=.55) or demand (p>.05)	Subjective: Cannabis users reported higher "Smoking Satisfaction" (p=.002) across all doses	Null (Cannabis use does not interfere with the efficacy of reduced nicotine cigarettes)

References

1. Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019. *Lancet*. Jun 19 2021;397(10292):2337–2360. doi:10.1016/s0140-6736(21)01169-7
2. Institute for Health M, Evaluation. Global Burden of Disease 2023. [online application]. 2025;
3. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. *Cochrane Database Syst Rev*. May 31 2013;2013(5):Cd009329. doi:10.1002/14651858.CD009329.pub2
4. Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. *Addiction*. Jan 2004;99(1):29–38. doi:10.1111/j.1360-0443.2004.00540.x
5. Evins AE, Benowitz NL, West R, et al. Neuropsychiatric Safety and Efficacy of Varenicline, Bupropion, and Nicotine Patch in Smokers With Psychotic, Anxiety, and Mood Disorders in the EAGLES Trial. *J Clin Psychopharmacol*. Mar/Apr 2019;39(2):108–116. doi:10.1097/jcp.0000000000001015
6. Babb S, Malarcher A, Schauer G, Asman K, Jamal A. Quitting Smoking Among Adults - United States, 2000-2015. *MMWR Morb Mortal Wkly Rep*. Jan 6 2017;65(52):1457–1464. doi:10.15585/mmwr.mm6552a1
7. Ebbert JO, Hughes JR, West RJ, et al. Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial. *Jama*. Feb 17 2015;313(7):687–94. doi:10.1001/jama.2015.280
8. Peters EN, Budney AJ, Carroll KM. Clinical correlates of co-occurring cannabis and tobacco use: a systematic review. *Addiction*. Aug 2012;107(8):1404–17. doi:10.1111/j.1360-0443.2012.03843.x
9. Costa GPA, Asnes S, De Aquino JP. Tobacco-cannabis co-use in adults ≥50: Trends, medical marijuana laws, and cessation implications-Letter to the Editor. *Am J Addict*. Nov 2025;34(6):682–683. doi:10.1111/ajad.70088
10. Reboussin BA, Wagoner KG, Ross JC, Suerken CK, Sutfin EL. Tobacco and marijuana co-use in a cohort of young adults: Patterns, correlates and reasons for co-use. *Drug Alcohol Depend*. Oct 1 2021;227:109000. doi:10.1016/j.drugalcdep.2021.109000
11. Akbar SA, Tomko RL, Salazar CA, Squeglia LM, McClure EA. Tobacco and cannabis co-use and interrelatedness among adults. *Addict Behav*. Mar 2019;90:354–361. doi:10.1016/j.addbeh.2018.11.036
12. Ream GL, Benoit E, Johnson BD, Dunlap E. Smoking tobacco along with marijuana increases symptoms of cannabis dependence. *Drug Alcohol Depend*. Jun 1 2008;95(3):199–208. doi:10.1016/j.drugalcdep.2008.01.011
13. Nguyen N, Bold KW, McClure EA. Urgent need for treatment addressing co-use of tobacco and cannabis: An updated review and considerations for future interventions. *Addict Behav*. Nov 2024;158:108118. doi:10.1016/j.addbeh.2024.108118
14. Agrawal A, Budney AJ, Lynskey MT. The co-occurring use and misuse of cannabis and tobacco: a review. *Addiction*. Jul 2012;107(7):1221–33. doi:10.1111/j.1360-0443.2012.03837.x

15. Tullis LM, Dupont R, Frost-Pineda K, Gold MS. Marijuana and tobacco: a major connection? *J Addict Dis*. 2003;22(3):51–62. doi:10.1300/J069v22n03_05
16. Lu HC, Mackie K. An Introduction to the Endogenous Cannabinoid System. *Biol Psychiatry*. Apr 1 2016;79(7):516–25. doi:10.1016/j.biopsych.2015.07.028
17. Marsicano G, Lutz B. Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. *Eur J Neurosci*. Dec 1999;11(12):4213–25. doi:10.1046/j.1460-9568.1999.00847.x
18. Herkenham M, Lynn AB, Little MD, et al. Cannabinoid receptor localization in brain. *Proc Natl Acad Sci U S A*. Mar 1990;87(5):1932–6. doi:10.1073/pnas.87.5.1932
19. Parsons LH, Hurd YL. Endocannabinoid signalling in reward and addiction. *Nat Rev Neurosci*. Oct 2015;16(10):579–94. doi:10.1038/nrn4004
20. Markou A. Review. Neurobiology of nicotine dependence. *Philos Trans R Soc Lond B Biol Sci*. Oct 12 2008;363(1507):3159–68. doi:10.1098/rstb.2008.0095
21. Adermark L, Morud J, Lotfi A, Ericson M, Söderpalm B. Acute and chronic modulation of striatal endocannabinoid-mediated plasticity by nicotine. *Addict Biol*. May 2019;24(3):355–363. doi:10.1111/adb.12598
22. Buczynski MW, Polis IY, Parsons LH. The volitional nature of nicotine exposure alters anandamide and oleoylethanolamide levels in the ventral tegmental area. *Neuropsychopharmacology*. Mar 2013;38(4):574–84. doi:10.1038/npp.2012.210
23. González S, Cascio MG, Fernández-Ruiz J, Fezza F, Di Marzo V, Ramos JA. Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. *Brain Res*. Nov 1 2002;954(1):73–81. doi:10.1016/s0006-8993(02)03344-9
24. Werling LL, Reed SC, Wade D, Izenwasser S. Chronic nicotine alters cannabinoid-mediated locomotor activity and receptor density in periadolescent but not adult male rats. *Int J Dev Neurosci*. May 2009;27(3):263–9. doi:10.1016/j.ijdevneu.2008.12.008
25. Marco EM, Granstrem O, Moreno E, et al. Subchronic nicotine exposure in adolescence induces long-term effects on hippocampal and striatal cannabinoid-CB1 and mu-opioid receptors in rats. *Eur J Pharmacol*. Feb 14 2007;557(1):37–43. doi:10.1016/j.ejphar.2006.11.013
26. Hirvonen J, Goodwin RS, Li CT, et al. Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. *Mol Psychiatry*. Jun 2012;17(6):642–9. doi:10.1038/mp.2011.82
27. Chen X, Williamson VS, An SS, et al. Cannabinoid receptor 1 gene association with nicotine dependence. *Arch Gen Psychiatry*. Jul 2008;65(7):816–24. doi:10.1001/archpsyc.65.7.816
28. Tyndale RF, Payne JI, Gerber AL, Sipe JC. The fatty acid amide hydrolase C385A (P129T) missense variant in cannabis users: studies of drug use and dependence in Caucasians. *Am J Med Genet B Neuropsychiatr Genet*. Jul 5 2007;144b(5):660–6. doi:10.1002/ajmg.b.30491
29. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021;372:n71. doi:10.1136/bmj.n71
30. Cohen C, Perrault G, Voltz C, Steinberg R, Soubrié P. SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-

releasing effects of nicotine in rats. *Behav Pharmacol*. Sep 2002;13(5-6):451–63. doi:10.1097/00008877-200209000-00018
31. Shoaib M. The cannabinoid antagonist AM251 attenuates nicotine self-administration and nicotine-seeking behaviour in rats. *Neuropharmacology*. Feb 2008;54(2):438–44. doi:10.1016/j.neuropharm.2007.10.011
32. Diergaarde L, de Vries W, Raasø H, Schoffelmeer AN, De Vries TJ. Contextual renewal of nicotine seeking in rats and its suppression by the cannabinoid-1 receptor antagonist Rimonabant (SR141716A). *Neuropharmacology*. Oct 2008;55(5):712–6. doi:10.1016/j.neuropharm.2008.06.003
33. de Bruin NM, Lange JH, Kruse CG, et al. SLV330, a cannabinoid CB(1) receptor antagonist, attenuates ethanol and nicotine seeking and improves inhibitory response control in rats. *Behav Brain Res*. Mar 1 2011;217(2):408–15. doi:10.1016/j.bbr.2010.11.013
34. Budzyńska B, Kruk M, Biała G. Effects of the cannabinoid CB1 receptor antagonist AM 251 on the reinstatement of nicotine-conditioned place preference by drug priming in rats. *Pharmacol Rep*. Mar–Apr 2009;61(2):304–10. doi:10.1016/s1734-1140(09)70036-2
35. Simonnet A, Cador M, Caille S. Nicotine reinforcement is reduced by cannabinoid CB1 receptor blockade in the ventral tegmental area. *Addict Biol*. Nov 2013;18(6):930–6. doi:10.1111/j.1369-1600.2012.00476.x
36. Abraham AD, Wiley JL, Marusich JA. Experimenter administered Δ(9)-THC decreases nicotine self-administration in a rat model. *Pharmacol Biochem Behav*. Oct 2023;231:173632. doi:10.1016/j.pbb.2023.173632
37. Gamaleddin I, Wertheim C, Zhu AZ, et al. Cannabinoid receptor stimulation increases motivation for nicotine and nicotine seeking. *Addict Biol*. Jan 2012;17(1):47–61. doi:10.1111/j.1369-1600.2011.00314.x
38. Cheeks SN, Buzzi B, Valdez A, Mogul AS, Damaj MI, Fowler CD. Cannabidiol as a potential cessation therapeutic: Effects on intravenous nicotine self-administration and withdrawal symptoms in mice. *Neuropharmacology*. Mar 15 2024;246:109833. doi:10.1016/j.neuropharm.2023.109833
39. Forget B, Coen KM, Le Foll B. Inhibition of fatty acid amide hydrolase reduces reinstatement of nicotine seeking but not break point for nicotine self-administration--comparison with CB(1) receptor blockade. *Psychopharmacology (Berl)*. Sep 2009;205(4):613–24. doi:10.1007/s00213-009-1569-5
40. Justinova Z, Panlilio LV, Moreno-Sanz G, et al. Effects of Fatty Acid Amide Hydrolase (FAAH) Inhibitors in Non-Human Primate Models of Nicotine Reward and Relapse. *Neuropsychopharmacology*. Aug 2015;40(9):2185–97. doi:10.1038/npp.2015.62
41. Gamaleddin I, Guranda M, Goldberg SR, Le Foll B. The selective anandamide transport inhibitor VDM11 attenuates reinstatement of nicotine seeking behaviour, but does not affect nicotine intake. *Br J Pharmacol*. Nov 2011;164(6):1652–60. doi:10.1111/j.1476-5381.2011.01440.x
42. Gamaleddin I, Guranda M, Scherma M, et al. AM404 attenuates reinstatement of nicotine seeking induced by nicotine-associated cues and nicotine priming but does not affect nicotine- and food-taking. *J Psychopharmacol*. Jun 2013;27(6):564–71. doi:10.1177/0269881113477710

43. Gamaleddin I, Zvonok A, Makriyannis A, Goldberg SR, Le Foll B. Effects of a selective cannabinoid CB2 agonist and antagonist on intravenous nicotine self administration and reinstatement of nicotine seeking. *PLoS One*. 2012;7(1):e29900. doi:10.1371/journal.pone.0029900
44. Xi ZX, Muldoon P, Wang XF, et al. Δ(8) -Tetrahydrocannabivarin has potent anti-nicotine effects in several rodent models of nicotine dependence. *Br J Pharmacol*. Dec 2019;176(24):4773–4784. doi:10.1111/bph.14844
45. Robinson JD, Cinciripini PM, Karam-Hage M, et al. Pooled analysis of three randomized, double-blind, placebo controlled trials with rimonabant for smoking cessation. *Addict Biol*. Jan 2018;23(1):291–303. doi:10.1111/adb.12508
46. Tonstad S, Aubin HJ. Efficacy of a dose range of surinabant, a cannabinoid receptor blocker, for smoking cessation: a randomized controlled clinical trial. *J Psychopharmacol*. Jul 2012;26(7):1003–9. doi:10.1177/0269881111431623
47. Morrison MF, Ceesay P, Gantz I, Kaufman KD, Lines CR. Randomized, controlled, double-blind trial of taranabant for smoking cessation. *Psychopharmacology (Berl)*. Apr 2010;209(3):245–53. doi:10.1007/s00213-010-1790-2
48. Morgan CJ, Das RK, Joye A, Curran HV, Kamboj SK. Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. *Addict Behav*. Sep 2013;38(9):2433–6. doi:10.1016/j.addbeh.2013.03.011
49. Hindocha C, Freeman TP, Grabski M, et al. Cannabidiol reverses attentional bias to cigarette cues in a human experimental model of tobacco withdrawal. *Addiction*. May 1 2018;113(9):1696–705. doi:10.1111/add.14243
50. Hindocha C, Freeman TP, Grabski M, et al. The effects of cannabidiol on impulsivity and memory during abstinence in cigarette dependent smokers. *Sci Rep*. May 15 2018;8(1):7568. doi:10.1038/s41598-018-25846-2
51. Gournay LR, Petry J, Bilsky S, et al. Cannabidiol Reduces Nicotine Withdrawal Severity and State Anxiety During an Acute E-cigarette Abstinence Period: A Novel, Open-Label Study. *Cannabis Cannabinoid Res*. Aug 2024;9(4):996–1005. doi:10.1089/can.2022.0317
52. Kelly TH, Foltin RW, Rose AJ, Fischman MW, Brady JV. Smoked marijuana effects on tobacco cigarette smoking behavior. *J Pharmacol Exp Ther*. Mar 1990;252(3):934–44.
53. Nemeth-Coslett R, Henningfield JE, O'Keeffe MK, Griffiths RR. Effects of marijuana smoking on subjective ratings and tobacco smoking. *Pharmacol Biochem Behav*. Sep 1986;25(3):659–65. doi:10.1016/0091-3057(86)90156-5
54. Peters EN, Herrmann ES, Smith C, et al. Impact of smoked cannabis on tobacco cigarette smoking intensity and subjective effects: A placebo-controlled, double-blind, within-subjects human laboratory study. *Exp Clin Psychopharmacol*. Aug 2021;29(4):345–354. doi:10.1037/pha0000391
55. Penetar DM, Kouri EM, Gross MM, et al. Transdermal nicotine alters some of marihuana's effects in male and female volunteers. *Drug Alcohol Depend*. Aug 1 2005;79(2):211–23. doi:10.1016/j.drugalcdep.2005.01.008
56. Gorey C, Kroon E, Runia N, Bornovalova M, Cousijn J. Direct Effects of Cannabis Intoxication on Motivations for Softer and Harder Drug Use: An Experimental Approach to the Gateway Hypothesis. *Cannabis Cannabinoid Res*. Jun 2024;9(3):e830–e838. doi:10.1089/can.2022.0157

57. Hindocha C, Freeman TP, Xia JX, Shaban NDC, Curran HV. Acute memory and psychotomimetic effects of cannabis and tobacco both 'joint' and individually: a placebo-controlled trial. *Psychol Med*. Nov 2017;47(15):2708–2719. doi:10.1017/s0033291717001222
58. Hindocha C, Lawn W, Freeman TP, Curran HV. Individual and combined effects of cannabis and tobacco on drug reward processing in non-dependent users. *Psychopharmacology (Berl)*. Nov 2017;234(21):3153–3163. doi:10.1007/s00213-017-4698-2
59. al'Absi M, DeAngelis BN, Nakajima M, et al. Biobehavioral and affective stress responses during nicotine withdrawal: Influence of regular cannabis co-use. *Psychopharmacology (Berl)*. Feb 2024;241(2):253–262. doi:10.1007/s00213-023-06481-w
60. Vandrey RG, Budney AJ, Hughes JR, Liguori A. A within-subject comparison of withdrawal symptoms during abstinence from cannabis, tobacco, and both substances. *Drug Alcohol Depend*. Jan 1 2008;92(1-3):48–54. doi:10.1016/j.drugalcdep.2007.06.010
61. Haney M, Bedi G, Cooper ZD, et al. Predictors of marijuana relapse in the human laboratory: robust impact of tobacco cigarette smoking status. *Biol Psychiatry*. Feb 1 2013;73(3):242–8. doi:10.1016/j.biopsych.2012.07.028
62. Parker MA, Streck JM, Bergeria CL, et al. Reduced Nicotine Content Cigarettes and Cannabis Use in Vulnerable Populations. *Tob Regul Sci*. Sep 2018;4(5):84–91. doi:10.18001/trs.4.5.8
63. West R, Evins AE, Benowitz NL, et al. Factors associated with the efficacy of smoking cessation treatments and predictors of smoking abstinence in EAGLES. *Addiction*. Aug 2018;113(8):1507–1516. doi:10.1111/add.14208
64. Constantin J, Jayawardhana J. Cigarette and cannabis use and co-use among U.S. adults: An examination of prevalence and trends during 2015-2023. *Addict Behav*. Jan 2026;172:108521. doi:10.1016/j.addbeh.2025.108521
65. Rubenstein D, McClernon FJ, Pacek LR. Trends in cannabis and tobacco co-use in the United States, 2002-2021. *Addict Behav*. Nov 2024;158:108129. doi:10.1016/j.addbeh.2024.108129
66. Panlilio LV, Zanettini C, Barnes C, Solinas M, Goldberg SR. Prior exposure to THC increases the addictive effects of nicotine in rats. *Neuropsychopharmacology*. Jun 2013;38(7):1198–208. doi:10.1038/npp.2013.16
67. Yeap ZJS, Marsault J, George TP, Mizrahi R, Rabin RA. Does tobacco dependence worsen cannabis withdrawal in people with and without schizophrenia-spectrum disorders? *Am J Addict*. Jul 2023;32(4):367–375. doi:10.1111/ajad.13394
68. Peng J, Fan M, An C, Ni F, Huang W, Luo J. A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD). *Basic Clin Pharmacol Toxicol*. Apr 2022;130(4):439–456. doi:10.1111/bcpt.13710